This article is more than 5 years old. Information may no longer be current.
Luxturna pricing tops January retina news
Click Here to Manage Email Alerts
News of Spark Therapeutics’ breakthrough gene therapy for inherited blindness being priced at $850,000 was the most-read retina-related article on Healio.com/OSN in January.
The company’s licensing agreement with Novartis for the treatment outside of the United States also made the list.
Here are the top five most-read retina articles from January:
1. Price for Spark ’ s gene therapy for blindness set at $850,000
The wholesale acquisition cost of one-time Luxturna treatment for confirmed biallelic RPE65 mutation-associated retinal dystrophy is $425,000 per eye. Read more.
2. Early results of new therapy for choroidal melanoma show promise
The light-activated AU-011 agent represents the first potential new therapy for choroidal melanoma in many decades, according to a speaker at Retina 2018 in Wailea, Hawaii. Read more.
3. First patient enrolled in Zimura trial for Stargardt disease
The randomized, double-masked, sham-controlled phase 2b clinical trial will assess the efficacy and safety of Zimura (avacincaptad pegol, Ophthotech), a complement C5 inhibitor, in 120 patients at more than 30 sites. Read more.
4. Novartis, Spark enter licensing agreement for Luxturna outside US
Novartis and Spark Therapeutics have entered a licensing agreement, with Novartis obtaining the rights to develop, register and commercialize Luxturna outside of the United States. Read more.
5. OCT for personalized anti-VEGF treatments saves US billions
OCT used to guide personalized anti-VEGF treatments for neovascular age-related macular degeneration patients saved the United States $9 billion. Read more.